-
What will be the new developments in the ICH Guidelines for 2020
Time of Update: 2020-06-07
The biennial ICH Conference was held in Singapore from November 16-20 In early November, at a public consultation session between the FDA and Health Canada in Ottawa, officials from two drug regulator
-
Tonghua Dongbao's first three generations of insulin glargine obtained clinical approval within months
Time of Update: 2020-04-03
According to the information on June 3 on the website of the State Food and Drug Administration (CFDA), the third-generation insulin glargine bulk drug and preparation insulin glargine injection that
-
The first domestic bevacizumab biological similar medicine is coming! Roche Aventine 2 billion status not guaranteed
Time of Update: 2019-12-10
Roche Aventine welcomes the challenger! On December 9, the State Food and Drug Administration issued an announcement to approve the application for listing and registration of bevacizumab injection (t
-
FDA biomarker testing standards are questioned
Time of Update: 2019-12-06
At one time, the certification of the food and Drug Administration (FDA) was the highest testing standard of food and drug in the world So many manufacturers in the world pursue FDA certification as t
-
BeiGene Zebutinib was approved by the FDA! Will it be listed simultaneously in China
Time of Update: 2019-11-15
Today, the first domestic anti-cancer drug approved by FDA is born! This morning, zanubrutinib, a Btk inhibitor in Baiji, was approved by the US FDA as a "breakthrough therapy"! It is used in the trea
-
Another 3 species passed the consistency evaluation; Fosun, humanwell and Neptune
Time of Update: 2019-04-10
Today morning, Haiwang biology released an enterprise announcement that its holding subsidiary Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd (hereinafter referred to as "Haiwang Fuyao") recently receiv
-
LVYE pharmaceutical ly03010 is approved to enter the global product portfolio of clinical central nervous system in the United States for further strengthening
Time of Update: 2018-09-27
September 26, 2018 / Meitong news agency / -- LVYE Pharmaceutical Group announced that the new drug, palipexone sustained-release suspension muscle injection (ly03010), independently developed by itse
-
Priority review + drug price negotiation! A new era of lung cancer treatment in China
Time of Update: 2018-06-19
The way of priority review has opened a green channel for these latest treatment schemes to enter the Chinese market Their coming implementation and application in China will bring good news to Chines
-
Parents note that another common drug for children is banned
Time of Update: 2018-06-04
[China Pharmaceutical network industry trends] recently, the State Food and Drug Administration announced that according to the results of adverse drug reaction monitoring and safety evaluation, in or
-
Will the "Anhui model" collapse and the two envelope bidding still make pharmaceutical companies miserable
Time of Update: 2015-11-05
Source: the formulation of Ames 2015-11-05 China's drug bidding policy has always blossomed, but the core goal has always been to reduce prices After all, there has never been a long-term universal oi
-
CFDA reminds us to pay attention to the risk of Chinese and Western medicine compound preparation
Time of Update: 2015-06-29
Source: CFDA 2015-6-29 the State Food and Drug Administration recently issued the 67th issue of adverse drug reaction information notice to remind the risk of Chinese and Western medicine compound pre
-
Weigh! Amgen bluemomab was approved by FDA quickly and became the first listed bispecific antibody
Time of Update: 2014-12-05
Source: biological exploration: two days before December 5, 2014, the author wrote a report "bispecific antibodies: new tools for cancer treatment, layout of pharmaceutical giants in succession", and
-
Safety first
Time of Update: 2013-09-18
The identification site of Chinese herbal medicine and Chinese herbal pieces is located on the second floor of Zhejiang Bawei specialty market At 7:30 a.m., the staff was in place From time to time, t
